Content by Keyword: Prescription Drugs

Basic report
How Does DATA-Waiver Provider Patient Capacity

How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief

How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief Robin Ghertner and Mir M. Ali U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation December 2020 Link to Printer Friendly Version in PDF Format (8 PDF pages)
PDF report
How Does DATA-Waiver Provider Patient Capacity

How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief

How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief Robin Ghertner and Mir M. Ali U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation December 2020 Link to HTML Version (8 PDF pages)
  • DATAWaiverIB.pdf
    export-csvPDF
Basic report
Postpartum Opioid Prescription Fills, Opioid Use

Postpartum Opioid Prescription Fills, Opioid Use Disorder, and Utilization of Medication-Assisted Treatment among Women with Medicaid and Private Health Insurance Coverage Issue Brief

Postpartum Opioid Prescription Fills, Opioid Use Disorder, and Utilization of Medication-Assisted Treatment among Women with Medicaid and Private Health Insurance Coverage Issue Brief Mir M. Ali, Kristina West, and Emma Nye U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation December 2
PDF report
Postpartum Opioid Prescription Fills, Opioid Use

Postpartum Opioid Prescription Fills, Opioid Use Disorder, and Utilization of Medication-Assisted Treatment among Women with Medicaid and Private Health Insurance Coverage Issue Brief

Postpartum Opioid Prescription Fills, Opioid Use Disorder, and Utilization of Medication-Assisted Treatment among Women with Medicaid and Private Health Insurance Coverage Issue Brief Mir M. Ali, Kristina West, and Emma Nye U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation December 2
  • PostpartOUDIB.pdf
    export-csvPDF
Site Page
Chart: Price Changes by Product - Text Version

Chart: Price Changes by Product - Text Version

Chart: Price Changes by Product, Post Blueprint Period in 2017 Compared to the Same Time Period in 2018
Site Page
This chart depicts price changes by product, post

Research

Home Generics and Biosimilars Reports to Congress Medicare Part B Research Prescription Drug Pricing: ASPE Resources Related to Safe Harbor Rule
Site Page
Medicare Part B Drug Spending

Medicare Part B Drug Spending

Home Generics and Biosimilars Reports to Congress Medicare Part B Research Medicare Part B Drugs: Trends in Spending and Utilization, 2006-2017
Site Page
Prescription Drug Pricing Reports to Congress

Prescription Drug Pricing Reports to Congress

Home Generics and Biosimilars Reports to Congress Medicare Part B Research
Site Page
Graph displaying the effects of moving to full

Incentivizing Generic and Biosimilar Product Uptake

Home Generic Drug Markets and Pricing Reports to Congress Medicare Part B Research
Site Page
Part D Gross Drug Costs Graph - Text Version

Part D Gross Drug Costs Graph - Text Version

Part D Gross Drug Costs, 2016, $US Billions MultiSource: $42.7 Brands: $8.7 Savings: $ Single souce: $102.0 Generics: $34.0 Spending if fully substituted: $5.9 Return to the Generic and Biosimilars page .
Site Page
Diagram illustrates the flow of goods, services,

Prescription Drugs

Home Generics and Biosimilars Reports to Congress Medicare Part B Research Comparing Insulin Prices in the U.S. to Other Countries
Site Page
Prescription Drugs: Flowchart Text Version

Prescription Drugs: Flowchart Text Version

Pharmaceutical supply chain includes 6 parties: payers, consumers, pharmacies, pharmacy benefits manager, distributor, and drug manufacturer.
PDF report
Current Estimates of Supply and Utilization of

Current Estimates of Supply and Utilization of Immune Globulin Products

In February 2007, the Eastern Research Group (ERG) submitted to the Office of the Assistant Secretary for Planning and Evaluation (ASPE) Analysis of Supply, Distribution, Demand, and Access Issues Associated with Immune Globulin Intravenous (IGIV) (2007 report).
  • IGIV_Market_Update.pdf
    export-csvPDF
Report page
Endnotes

Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Endnotes

1 - Claritin, Premarin, Zantac, Prozac, Trimox, Prilosec, Lanoxin, Hydrocodone w/APAP, Norvasc, Lipitor, Furosemide, Synthroid, Coumadin, Vasotec, Atenolol, Lasix, Triamterene/HCTZ, Cardizem CD, Hydrochlorothiazide, Zestril, Prednisone, K-Dur, Zocor, Procardia XL, and Glyburide. 2 - Analysis using a different set of drugs might yield different r
Report page
Cash Share of the Market

Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Cash Share of the Market

Cash payments have accounted for a declining share of the retail market for prescription drugs, as noted in Chapter 3. The share of prescriptions for which the purchaser pays in cash at the time of the transaction has declined from 63 percent in 1990 to 25 percent in 1998. 4 One possible explanation for some of the differences just observed could
Report page
Prescription Drug Prices

Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Prescription Drug Prices

Given the national nature of many of the major players in the prescription drug market—drugs are produced by national manufacturers, distributed through mostly national PBMs and in many cases through national pharmacy chains—we might not expect to see large price differences by region. We would expect to see small differences based on local pr
Report page
Utilization and Spending

Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Utilization and Spending

In Chapter 2, various data were presented that showed spending differences between individuals with and without insurance coverage for prescription drugs. Here we consider those same comparisons within regions. Because size of prescription may vary due to differences in local medical practice patterns and variations in state Medicaid regulations o
Report page
Coverage

Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Coverage

Table C-1 shows variation in coverage levels by region using MEPS data on drug coverage for the civilian, noninstitutionalized population. The highest coverage rates are in the Midwest and Northeast with the lowest coverage rate in the South. The pattern observed is similar to analyses of general health insurance coverage elsewhere.
Report page
Appendix C. State and Regional Variations

Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Appendix C. State and Regional Variations

One area of inquiry that is not discussed in the main report is regional and state variation. Preliminary analysis from several different sources suggests that there are substantial regional and state variations in spending and utilization of prescription drugs and in prices faced by consumers. At this point, we can observe some differences, but w
Report page
Endnotes

Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Endnotes

1 - The one exception was Medicare HMO coverage, which was identified through HCFA(now known as CMS) enrollment records. 2 -The MEPS estimates are adjusted for two reasons. First, the adjusted MEPS estimates can be directly compared to the MCBS estimates. Second, the unadjusted MEPS estimates would overstate the percentage of beneficiaries who h

Pages